Triple-negative breast cancer (TNBC) is a type of breast cancer without the expression of estrogen receptors (ER), progesterone receptors (PR), and HER2 protein. TNBC is more likely to metastasize, recur, and there are no good targeted therapies compared with other breast cancer types, making it a challenge for optimizing the prognosis of patients. However, in recent years studies brought to attention that due to higher mutation burdens, TNBC has higher tumor-infiltrating lymphocytes (TIL) compared with other breast cancer, and the level of TIL is correlated with a better prognosis of TNBC patients. Moreover, TNBC is most likely to be lymphocyte-predominant breast cancer (LPBC, with TIL level>50%), which has a much higher response rate to immunotherapy. All this fact suggests that immunotherapy would be a good cancer therapy for TNBC.
Although TNBC is more likely to be immunotherapy responsive, up-to-date clinical studies still show that the overall response rate of TNBC is about ~20%. This could be caused by many different mechanisms such as local immunosuppressive microenvironment, malfunctioning interactions between immune cells and cancer cells, or between different immune cell types. In certain circumstances, it may also be caused by the inability of immune cells to properly recognize the cancer cells. The goal of this Research Topic is to show the potential new methods to overcome immunotherapy resistance and achieve the best prognosis for TNBC patients. The other goal is to include up-to-date personalized immunotherapy studies such as CAR-T and cancer vaccine in TNBC.
We welcome submissions on:
- up-to-date immunotherapy studies in TNBC, including immune checking point inhibitors such as PD-1, PD-L1, and CTLA-4 inhibitors;
- personalized immunotherapies in TNBC including CAR-T, mRNA vaccine, and so on;
- other therapeutical methods which can overcome immunotherapy resistance. We are also interested in Review articles in this area.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Triple-negative breast cancer (TNBC) is a type of breast cancer without the expression of estrogen receptors (ER), progesterone receptors (PR), and HER2 protein. TNBC is more likely to metastasize, recur, and there are no good targeted therapies compared with other breast cancer types, making it a challenge for optimizing the prognosis of patients. However, in recent years studies brought to attention that due to higher mutation burdens, TNBC has higher tumor-infiltrating lymphocytes (TIL) compared with other breast cancer, and the level of TIL is correlated with a better prognosis of TNBC patients. Moreover, TNBC is most likely to be lymphocyte-predominant breast cancer (LPBC, with TIL level>50%), which has a much higher response rate to immunotherapy. All this fact suggests that immunotherapy would be a good cancer therapy for TNBC.
Although TNBC is more likely to be immunotherapy responsive, up-to-date clinical studies still show that the overall response rate of TNBC is about ~20%. This could be caused by many different mechanisms such as local immunosuppressive microenvironment, malfunctioning interactions between immune cells and cancer cells, or between different immune cell types. In certain circumstances, it may also be caused by the inability of immune cells to properly recognize the cancer cells. The goal of this Research Topic is to show the potential new methods to overcome immunotherapy resistance and achieve the best prognosis for TNBC patients. The other goal is to include up-to-date personalized immunotherapy studies such as CAR-T and cancer vaccine in TNBC.
We welcome submissions on:
- up-to-date immunotherapy studies in TNBC, including immune checking point inhibitors such as PD-1, PD-L1, and CTLA-4 inhibitors;
- personalized immunotherapies in TNBC including CAR-T, mRNA vaccine, and so on;
- other therapeutical methods which can overcome immunotherapy resistance. We are also interested in Review articles in this area.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
